腹腔内灌注紫杉醇治疗恶性腹水近期疗效

目的：观察紫杉醇腹腔内灌注对治疗恶性腹水的近期疗效。方法18例恶性腹水患者随机、双盲分为紫杉醇组和顺铂组，采用对照研究，分别于腹腔积液尽量排净后，给予腹腔内灌注紫杉醇或顺铂。每周1次，连续3周。结果紫杉醇组临床总有效率为88.9%，顺铂组临床总有效率为55.6%，两组相比差异具有统计学意义（P〈0.05）。紫杉醇组生活质量改善较顺铂组明显，两组药物不良反应差异无统计学意义（P〉0.05）。结论腹腔内灌注紫杉醇治疗恶性腹水近期疗效较好，操作简单方便、不良反应少，是一种前景较好的治疗方法。

Short-term curative effect of intraperitoneal perfusion paclitaxel in the treatment of malignant ascites

Objective To observe the the recent curative effect of taxol intraperitoneal perfusion of for the treatment of malignant ascites. Methods 18 patients with malignant ascites in random and double-blind are divided into paclitaxel and cisplatin groups, with contrast study, in the abdominal cavity effusion complete as far as possible, worked in intraperitoneal perfusion paclitaxel and cisplatin respectively. Once a week, for three weeks. Results Paclitaxel group clinical total effective rate was 88.9%, and cisplatin group clinical total effective rate was 55.6%. Comparison between two groups has significant difference （P〈0.05）. Paclitaxel quality of life for improvement was more obvious than the cisplatin. No distinct difference between the two groups of drug on adverse reactions. Conclusion Intraperitoneal perfusion with paclitaxel in the mid of curing malignant ascites, the near future curative effect is good, and easy and convenient operation, less side effects and is a good treatment for prospect.